PepGen early trial shows promise for myotonic dystrophy drug

PepGen reported early-stage trial data indicating its candidate corrects more of the genetic stutter in myotonic dystrophy type 1. The results are preliminary and not yet peer-reviewed, with efficacy and safety still uncertain. This is a notable but early development in a niche therapeutic area, unlikely to have broad market impact.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works